Cargando…
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation
BACKGROUND: Immunization of mice with tumor homogenate after combined treatment with cyclophosphamide (CP) and double-stranded DNA (dsDNA) preparation is effective at inhibition of growth of tumor challenged after the treatment. It was assumed that this inhibition might be due to activation of the a...
Autores principales: | Alyamkina, Ekaterina A, Nikolin, Valeriy P, Popova, Nelly A, Dolgova, Evgenia V, Proskurina, Anastasia S, Orishchenko, Konstantin E, Efremov, Yaroslav R, Chernykh, Elena R, Ostanin, Alexandr A, Sidorov, Sergey V, Ponomarenko, Dmitriy M, Zagrebelniy, Stanislav N, Bogachev, Sergey S, Shurdov, Mikhail A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987767/ https://www.ncbi.nlm.nih.gov/pubmed/21040569 http://dx.doi.org/10.1186/1479-0556-8-7 |
Ejemplares similares
-
Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice
por: Alyamkina, Ekaterina A, et al.
Publicado: (2009) -
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer
por: Proskurina, Anastasia S., et al.
Publicado: (2016) -
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer
por: Proskurina, Anastasia S, et al.
Publicado: (2015) -
Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts
por: Alyamkina, Ekaterina A, et al.
Publicado: (2015) -
Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called “Karanahan” Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model
por: Ruzanova, Vera, et al.
Publicado: (2022)